Axon Enterprise, Inc $AXON Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lowered its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 13.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,359 shares of the biotechnology company’s stock after selling 1,277 shares during the period. Corient Private Wealth LLC’s holdings in Axon Enterprise were worth $4,747,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of AXON. Darwin Wealth Management LLC acquired a new stake in Axon Enterprise during the 2nd quarter worth about $37,000. Creative Financial Designs Inc. ADV acquired a new position in shares of Axon Enterprise in the fourth quarter worth about $28,000. Sound Income Strategies LLC boosted its holdings in shares of Axon Enterprise by 550.0% in the fourth quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock worth $30,000 after buying an additional 44 shares during the period. Camelot Portfolios LLC purchased a new position in shares of Axon Enterprise in the fourth quarter worth approximately $30,000. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Axon Enterprise in the fourth quarter worth approximately $34,000. 79.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on AXON shares. Barclays reduced their price target on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Morgan Stanley set a $600.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. Piper Sandler reissued an “overweight” rating and set a $674.00 target price on shares of Axon Enterprise in a research note on Monday, June 15th. Citizens Jmp restated a “market outperform” rating and issued a $700.00 target price on shares of Axon Enterprise in a report on Thursday. Finally, Weiss Ratings raised Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock opened at $465.12 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The company has a market cap of $37.49 billion, a PE ratio of 186.79, a price-to-earnings-growth ratio of 8.09 and a beta of 1.45. The firm has a fifty day moving average price of $420.65 and a two-hundred day moving average price of $482.08. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.90 million. During the same quarter in the previous year, the firm posted $1.47 EPS. The business’s revenue was up 33.7% compared to the same quarter last year. Analysts expect that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 20,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $10,000,000.00. Following the sale, the chief executive officer owned 3,060,997 shares of the company’s stock, valued at $1,530,498,500. The trade was a 0.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $485.00, for a total transaction of $753,690.00. Following the completion of the sale, the insider directly owned 34,024 shares in the company, valued at approximately $16,501,640. The trade was a 4.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 38,989 shares of company stock worth $19,090,083. Insiders own 4.20% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.